← All trials
NCT01404260
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2011
- Primary completion
- Mar 1, 2015
- Completion date
- Oct 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 219
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Guangdong Association of Clinical TrialsLead sponsor
- First People's Hospital of HangzhouCollaborator
- Fudan UniversityCollaborator
- Wuxi No. 4 People's HospitalCollaborator
- Changhai HospitalCollaborator
- Henan Medical UniversityCollaborator
- Guangdong Province Clinical Trial AssociationOverall official - principal investigator
- Zhejiang UniversityCollaborator
- Jilin UniversityCollaborator
- Soochow UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- Guangdong Association of Clinical TrialsReponsible party - principal investigator
- People's Liberation Army of ChinaCollaborator
- Jiao Tong UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.